

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schülein et al.

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: May 23, 2000

Examiner: To be assigned

For: Family 9 Endo-Beta-1,4-Glucanases

**SEQUENCE AMENDMENT**

Box Sequence  
Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Applicants respectfully request the amendment of the above-captioned application as follows:

**IN THE SPECIFICATION:**

- On page 27, at the end of line 7, please insert --(SEQ ID NO: 1)--.
- On page 27, at the end of line 9, please insert --(SEQ ID NO: 2)--.
- On page 27, at the end of line 20, please insert --(SEQ ID NO: 3)--.
- On page 27, at the end of line 21, please insert --(SEQ ID NO: 4)--.
- On page 27, at the end of line 30, please insert --(SEQ ID NO: 5)--.
- On page 27, at the end of line 31, please insert --(SEQ ID NO: 6)--.
- On page 30, at the end of line 10, please insert --(SEQ ID NO: 7)--.
- On page 30, at the end of line 13, please insert --(SEQ ID NO: 8)--.

**REMARKS**

Applicants enclose herewith the Sequence Listing for the above-captioned

application and a 3.5" floppy disk containing the Sequence Listing.


The specification has been amended to provide SEQ ID NOS for the sequences disclosed therein. This submission contains no new matter.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 23, 2000

  
\_\_\_\_\_  
Reza Green, Reg. No. 38,475  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123